Successful trovafloxacin prophylaxis against experimental streptococcal aortic valve endocarditis.
Single-dose trovafloxacin (15 mg/kg given intravenously [i.v.]) and ampicillin (40 mg/kg given i.v.) protected 38 and 33% of animals challenged with an ampicillin-tolerant strain of Streptococcus oralis, respectively. As a double-dose regimen, trovafloxacin afforded total protection (100%; P < 0.001 versus controls). Trovafloxacin is the first fluoroquinolone effective in preventing experimental streptococcal endocarditis.
Katsarolis
I
I
4th Department of Medicine, Sismanoglion General Hospital, Athens, Greece. aikat@ath.forthnet.gr
Pefanis
A
A
Iliopoulos
D
D
Siaperas
P
P
Karayiannakos
P
P
Giamarellou
H
H
D000667:Ampicillin / Q000627:therapeutic use; D000818:Animals; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D001021:Aortic Valve / Q000382:microbiology*; D004195:Disease Models, Animal; D004697:Endocarditis, Bacterial / Q000517:prevention & control*; D005260:Female; D024841:Fluoroquinolones; D006349:Heart Valve Diseases / Q000188:drug therapy / Q000382:microbiology; D008826:Microbial Sensitivity Tests; D009287:Naphthyridines / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use; D011817:Rabbits; D013290:Streptococcal Infections / Q000517:prevention & control*; D013291:Streptococcus / Q000187:drug effects
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D010406:Penicillins; D000667:Ampicillin; C080163:trovafloxacin